Core Insights - Amgen reported $9.18 billion in revenue for the quarter ended June 2025, a year-over-year increase of 9.4%, with an EPS of $6.02 compared to $4.97 a year ago, exceeding both revenue and EPS consensus estimates [1] Financial Performance - Revenue from product sales reached $8.77 billion, surpassing the average estimate of $8.5 billion, reflecting a 9.1% increase year-over-year [4] - Other revenues amounted to $408 million, exceeding the average estimate of $345.97 million, representing a year-over-year increase of 17.6% [4] - The EPS surprise was +14.45% compared to the consensus estimate of $5.26 [1] Product Sales Breakdown - Neulasta (ROW) sales were $19 million, below the estimate of $23.31 million, showing a year-over-year decline of 36.7% [4] - Neulasta (U.S.) sales were $63 million, compared to the estimate of $70.64 million, reflecting a 16% year-over-year decrease [4] - Otezla (ROW) sales were $106 million, slightly below the estimate of $112.78 million, with a year-over-year decline of 5.4% [4] - Nplate (U.S.) sales were $228 million, slightly above the estimate of $227.77 million, showing a year-over-year increase of 6.5% [4] - Vectibix sales totaled $305 million, exceeding the estimate of $277.53 million, with a year-over-year increase of 13% [4] - BLINCYTO sales were $384 million, slightly below the estimate of $385.77 million, but represented a significant year-over-year increase of 45.5% [4] - Enbrel sales were $604 million, significantly below the estimate of $804.22 million, reflecting a year-over-year decline of 33.6% [4] - LUMAKRAS/LUMYKRAS sales were $90 million, in line with the estimate of $90.65 million, showing a year-over-year increase of 5.9% [4] Stock Performance - Amgen's shares returned +3.1% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Viewpoint - Amgen is expected to report quarterly earnings of $5.25 per share, reflecting a 5.6% increase year-over-year, with revenues forecasted at $8.86 billion, also representing a 5.6% year-over-year increase [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.2%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue and Product Sales Estimates - The consensus estimate for 'Revenue- Product sales' is $8.49 billion, indicating a year-over-year change of +5.6% [5]. - Analysts project 'Product Sales- Neulasta- Total' to reach $92.14 million, reflecting a -12.3% change from the previous year [5]. - 'Product Sales- LUMAKRAS/LUMYKRAS- Total' is expected to be $91.20 million, showing a +7.3% year-over-year change [5]. - 'Product Sales- Otezla- Total' is estimated at $533.54 million, indicating a -1.9% change year-over-year [6]. - 'Product Sales- Neulasta- ROW' is projected at $23.31 million, reflecting a -22.3% change year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is expected to be $66.88 million, indicating a -10.8% change from the prior year [6]. - 'Product Sales- Vectibix- ROW' is estimated at $135.60 million, showing a -1% change from the previous year [7]. - 'Product Sales- Vectibix- U.S.' is forecasted to reach $141.96 million, reflecting a +6.7% year-over-year change [7]. - 'Product Sales- Enbrel- U.S.' is expected to be $786.00 million, indicating a -12.9% change from the prior year [7]. - 'Product Sales- Enbrel- ROW' is projected at $7.01 million, reflecting a +0.1% change year-over-year [8]. - 'Product Sales- Aranesp- ROW' is estimated at $251.00 million, indicating a -2.3% change year-over-year [8]. - 'Product Sales- Aranesp- U.S.' is expected to be $80.25 million, reflecting a -11.8% change from the previous year [8]. Stock Performance - Over the past month, Amgen shares have recorded a return of +1.5%, compared to the Zacks S&P 500 composite's +2.7% change [9].